Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review

@article{Franchini2007PotentialRO,
  title={Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review},
  author={Massimo Franchini and Franco Manzato and Gian Luca Salvagno and Giuseppe Lippi},
  journal={Blood Coagulation \& Fibrinolysis},
  year={2007},
  volume={18},
  pages={589–593}
}
Recombinant activated factor VII (rFVIIa) is a novel hemostatic agent, originally developed for the treatment of hemorrhage in hemophiliacs with inhibitors, which has been successfully used recently in an increasing number of nonhemophilic bleeding conditions. In the present systematic review we report the existing literature data on the use of this hemostatic agent in severe bleeding, unresponsive to standard treatment, associated with disseminated intravascular coagulation. A total of 99… Expand
The Use of Recombinant Activated FVII in Postpartum Hemorrhage
TLDR
A critical analysis of the published literature on the use of recombinant activated factor VII (rF VIIa) in severe PPH was performed and some recommendations and an algorithm on the therapeutic role of rFVIIa in the management of PPH were included. Expand
Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies
TLDR
Large randomized, phase III clinical trials investigated the efficacy of antithrombin (AT), activated protein C (APC), tissue factor pathway inhibitor (TFPI), and thrombomodulin (TM) in patients with sepsis, but the diagnosis of DIC was not part of the inclusion criteria. Expand
Successful management by recombinant activated factor VII in a case of disseminated intravascular coagulopathy caused by obstetric hemorrhage
TLDR
A case of successful treatment with rFVIIa for PPH due to placenta accreta is described, a 33‐year‐old woman with placental previa who was diagnosed with massive hemorrhage during Cesarean section. Expand
Prophylactic use of NovoSeven in surgical procedures in a patient with coagulation disorders in the course of abdominal actinomycosis
TLDR
Preoperative use of NovoSeven resulted in reducing significant perioperative bleedings and there was a decrease in the requirement for postoperative blood transfusions, particularly in patients with complex coagulopathy. Expand
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
TLDR
The effectiveness of rFVIIa as a more general haemostatic drug, either prophylactically or therapeutically, remains unproven and its use outside its current licensed indications should be restricted to clinical trials. Expand
Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage
TLDR
This study reports a case of severe PPH complicated by disseminated intravascular coagulation (DIC), in which early rFVIIa administration not only failed to control the bleeding in vivo but also, surprisingly, failed to correct the patient's international normalized ratio (INR) in vitro. Expand
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
TLDR
The effectiveness of rFVIIa when used therapeutically to control active bleeding or prophylactically to prevent (excessive) bleeding in patients without haemophilia is assessed. Expand
A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage.
TLDR
Although the potential role of rFVIIa in treating massive postpartum hemorrhage refractory to standard therapy is suggested, further evidence is needed using well-designed clinical trials to better assess the optimal dose, the effectiveness, and the safety of the novel agent in such critical bleeding conditions. Expand
Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature
TLDR
The successful use of rFVIIa is described in a patient with acute ICH in the setting of newly diagnosed AML. Expand
Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications
TLDR
The experience with rFVIIa in patients with refractory bleeding after lung transplant surgery is reported, and all attempts are made to minimize large blood transfusions in this cohort. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Use of recombinant FVIIa for intraperitoneal coagulopathic bleeding in a septic patient.
TLDR
Recombinant activated coagulation factor VII (rFVIIa) is a U.S. Food and Drug Administration-approved drug for use in hemophiliacs with inhibitors and corrects the platelet defects associated with Glanzmanns thrombasthenia, Bernard Soulier syndrome, uremia, and other severe congenital and acquiredThrombocytopathias. Expand
Recombinant activated factor VII for adjunctive hemorrhage control in trauma.
TLDR
The results of this report suggest that in trauma patients rFVIIa may play a role as an adjunctive hemostatic measure, in addition to surgical he mostatic techniques, and provides the motivation for controlled animal and clinical trials. Expand
Use of Recombinant Activated Factor VII for Bleeding in Pancreatitis: A Case Series
Objectives: To describe the effects of recombinant activated factor VII (rFVIIa) in the treatment of bleeding in a series of patients with acute or chronic pancreatitis. Methods: Twelve patientsExpand
Successful treatment of severe intra‐abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII
TLDR
A pregnant woman with DIC, who developed severe intra‐abdominal bleeding after caesarean section, is reported, suggesting a potential role for rFVIIa in the treatment of severe and refractory bleeding associated with D IC. Expand
Treatment of intra-abdominal bleeding with recombinant activated factor VII in a patient with disseminated intravascular coagulation secondary to septic shock.
TLDR
A man with DIC and septic shock due to retrocaecal appendicitis and severe intra-abdominal bleeding after surgery is reported, suggesting a potential role of rFVIIa in the treatment of severe bleeding associated with D IC. Expand
Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation
TLDR
Evidence is provided that rFVIIa can be used successfully to control the hemorrhagic episodes associated with DIC and although this type of treatment appears to be safe, close monitoring of the patients is warranted. Expand
Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: A break from convention in need of controlled trials
TLDR
The antihemophilic agent recombinant activated factor VII (rFVIIa) development has led to a fundamental re‐evaluation of the classic understanding of the normal clotting cascade and use of this product in liver disease patients is increasing despite the lack of definitive studies or literature to guide therapy. Expand
The use of recombinant activated factor VII in the treatment of massive pulmonary hemorrhage in a preterm infant.
TLDR
The case of massive pulmonary hemorrhage in a 9-day-old male infant, successfully treated with intravenous recombinant activated factor VII (rF VIIa) (NovoSeven; Novo Nordisk) suggests that rFVIIa is effective as an alternative therapy in controlling massivemonary hemorrhage of preterm infants. Expand
Mechanism of action of recombinant factor VIIa
TLDR
Experiments are described which confirm and extend the concepts on a TF-dependent mechanism of action of rFVIIa and show that both in a system consisting of purified proteins, and in a whole blood system, reduced and delayed thrombin generation in situations mimicking hemophilia are only restored to normal values by rFVI if large quantities of platelets are present. Expand
Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective
TLDR
There is a rationale for using rFVIIa to treat massive bleeding in certain indications, but only adjunctively to the surgical control of bleeding once conventional therapies have failed. Expand
...
1
2
3
4
5
...